{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T21:24:09Z","timestamp":1792185849654,"version":"4.4.0"},"reference-count":17,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2020,12,28]],"date-time":"2020-12-28T00:00:00Z","timestamp":1609113600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["obgyn.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["J of Obstet and Gynaecol"],"published-print":{"date-parts":[[2021,3]]},"abstract":"Abstract<\/jats:title>Aim<\/jats:title>To evaluate the clinical efficacy of biosimilar (Ovaleap) compared with the referenced follitropin alfa (Gonal\u2010f), within the context of antagonistic multiple doses protocol of controlled ovarian hyperstimulation (COH) for in vitro fertilization (IVF) or intracytoplasmic sperm injection (ICSI) techniques.<\/jats:p><\/jats:sec>Methods<\/jats:title>A retrospective, monocentric study included 229 infertile women aged 22 to 43\u2009years who underwent their first cycle of COH for the purpose of the IVF or ICSI during the period of 2017. Eligible patients underwent ovarian stimulation with either Ovaleap (n<\/jats:italic> = 152) or Gonal\u2010f (n<\/jats:italic> = 77) starting at Cycle Day 2 and were receiving gonadotropin\u2010releasing hormone (GnRH) antagonist in either fixed or flexible antagonist protocol manner.<\/jats:p><\/jats:sec>Results<\/jats:title>Ovaleap\u2010treatment resulted in fewer number of oocytes retrieved in regard to Gonal\u2010f\u2010treatment, with the median of seven oocytes retrieved in the Ovaleap group versus nine in the Gonal\u2010f group (U<\/jats:italic> = 5369.5, P<\/jats:italic> = 0.3079). Clinical pregnancy rate was 24.3% in the overall study sample and 31.9% in women with embryo transfer, in the Ovaleap group. Similarly, in the Gonal\u2010f group these rates were 25.0% and 34.5%, respectively. Only four patients experienced ovarian hyperstimulation syndrome, with one case in Ovaleap\u2010treatment group and three cases in Gonal\u2010f\u2010treatment group.<\/jats:p><\/jats:sec>Conclusion<\/jats:title>While the clinical efficacy profile favored using Gonal\u2010f formulation of follitropin alfa, this analysis showed that there is no significant difference in the number of oocytes retrieved between Ovaleap and Gonal\u2010f follitropin alfa formulations, used within GnRH antagonist protocols of COH.<\/jats:p><\/jats:sec>","DOI":"10.1111\/jog.14626","type":"journal-article","created":{"date-parts":[[2020,12,29]],"date-time":"2020-12-29T08:00:32Z","timestamp":1609228832000},"page":"992-1001","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Retrospective analysis of the use of two recombinant follitropin alfa injections in patients undergoing in vitro fertilization treatment with the gonadotropin\u2010releasing hormone antagonist protocol"],"prefix":"10.1111","volume":"47","author":[{"given":"Marina","family":"\u0160prem Gold\u0161tajn","sequence":"first","affiliation":[{"name":"Department of Obstetrics and Gynecology University Hospital Center Zagreb Zagreb Croatia"},{"name":"School of Medicine, University of Zagreb Zagreb Croatia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stipe","family":"Duman\u010di\u0107","sequence":"additional","affiliation":[{"name":"School of Medicine, University of Zagreb Zagreb Croatia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1365-8704","authenticated-orcid":false,"given":"Mislav","family":"Miku\u0161","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology University Hospital Center Zagreb Zagreb Croatia"},{"name":"School of Medicine, University of Zagreb Zagreb Croatia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2020,12,28]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12958-016-0167-8"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0184139"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40268-017-0182-z"},{"key":"e_1_2_8_5_1","doi-asserted-by":"crossref","unstructured":"LispiM MastrangeliR GalanoE PalmeseA CutilloF CasariniL RiccettiL LongobardiS SimoniM.Comparative Analysis of Structural Differences of Ovaleap and GONAL\u2010f: Site\u2010specific Glycosylation Mapping and Cell Signalling Activation. Poster presented at: 34th Annual Meeting of the European Society of Human Reproduction and Embryology; 1\u20134 July 2018 Barcelona Spain.","DOI":"10.26226\/morressier.5af300b2738ab10027aa9961"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13318-015-0257-6"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.2147\/IJWH.S83418"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12958-015-0124-y"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.rbmo.2015.01.005"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12958-015-0135-8"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12958-016-0164-y"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.fertnstert.2019.07.629"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1093\/humrep\/den468"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1093\/humupd\/dml038"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1093\/humrep\/dem254"},{"key":"e_1_2_8_16_1","unstructured":"European Medicines Agency (EMA):Note for guidance on Specifications: Test procedures and acceptance criteria for Biotechnological\/Biological Products CPMP\/ICH\/365\/96 ICH Q6B. [accessed: 10.08.2020.]Available from URL:https:\/\/www.ema.europa.eu\/en\/documents\/scientific\u2010guideline\/ich\u2010q\u20106\u2010b\u2010test\u2010procedures\u2010acceptance\u2010criteria\u2010biotechnological\/biological\u2010products\u2010step\u20105_en.pdf"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.fertnstert.2003.07.027"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1093\/humrep\/17.11.2842"}],"container-title":["Journal of Obstetrics and Gynaecology Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jog.14626","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/jog.14626","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/obgyn.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jog.14626","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,2]],"date-time":"2023-09-02T08:36:03Z","timestamp":1693643763000},"score":1,"resource":{"primary":{"URL":"https:\/\/obgyn.onlinelibrary.wiley.com\/doi\/10.1111\/jog.14626"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,28]]},"references-count":17,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,3]]}},"alternative-id":["10.1111\/jog.14626"],"URL":"https:\/\/doi.org\/10.1111\/jog.14626","archive":["Portico"],"relation":{},"ISSN":["1341-8076","1447-0756"],"issn-type":[{"value":"1341-8076","type":"print"},{"value":"1447-0756","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,12,28]]},"assertion":[{"value":"2020-09-21","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-12-12","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-12-28","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}